STO · EPIS-B.ST
Episurf Medical AB
SEK 0.06-SEK 0.00 (-1.35%)
Episurf Medical AB’s quoted price sits in the lower half of its reported 52-week range, 79.83% below the high.
Loading market information…
STO · 2CUREX.ST · SEK
Stock price, dividends, earnings
Quote as of Aug 31, 2026, 03:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
2cureX AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.16% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow 2cureX AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Copenhagen, Denmark, 2cureX AB (publ) is a European medtech firm established in 2006. The company's core offering is IndiTreat, an in-vitro diagnostic test designed to forecast how cancer patients will respond to or resist various drug treatments, thereby guiding clinicians in selecting the most effective therapy. Additionally, 2cureX is actively advancing IndiTreat through clinical programs targeting a range of cancers, including breast, colorectal, ovarian, and pancreatic types.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
SEK 0.06-SEK 0.00 (-1.35%)
Episurf Medical AB’s quoted price sits in the lower half of its reported 52-week range, 79.83% below the high.
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
SEK 1.08-SEK 0.01 (-1.28%)
Qlife Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 71.47% below the high.
SEK 1.47SEK 0.00 (0.0%)
Guard Therapeutics International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.56% below the high.
SEK 1.33-SEK 0.04 (-2.92%)
ODI Pharma AB’s quoted price sits in the lower half of its reported 52-week range, 75.6% below the high.
SEK 0.18-SEK 0.00 (-2.2%)
Modus Therapeutics Holding AB’s quoted price sits in the lower half of its reported 52-week range, 70.13% below the high.
SEK 0.21SEK 0.00 (0.0%)
Stayble Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
SEK 0.27SEK 0.00 (0.0%)
Aptahem AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 86.21% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
